COMMUNIQUÉS West-GlobeNewswire

Rule 2.9 Announcement
20/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 November 2018 [...]
DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
20/11/2018
Montrouge, France, November 20, 2018 DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children Three oral presentations highlighted analyses from the [...]
DBV Technologies présente à l'ACAAI 2018 des données relatives à Viaskin Peanut, un médicament expérimental pour le traitement de l'allergie à l'arachide chez les enfants
20/11/2018
Montrouge, France, le 20 Novembre (07h30 CET), 2018 DBV Technologies présente à l'ACAAI 2018 des données relatives à Viaskin Peanut, un médicament expérimental pour le traitement de l'allergie à l'arachide chez les [...]
Innate Pharma appoints experts to new Strategic Advisory Board
20/11/2018
Innate PHARMA APPOINTS EXPERTS TO NEW strategic advisory board Marseille, France, November 20, 2018, 07:00 AM CEST Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced the appointment of [...]
Innate Pharma nomme son nouveau Conseil Stratégique composé d'experts en immuno-oncologie
20/11/2018
Innate PHARMA nomme son nouveau conseil strategique COMPOSÉ D'EXPERTS EN IMMUNO-ONCOLOGIE Marseille, France, le 20 novembre 2018, 07h00 Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) a annoncé [...]
Avivagen Announces Clarification to Press Release Issued November 19, 2018
20/11/2018
OTTAWA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen”), announces a clarification to its press release issued Monday, November 19 th at 6:30 A.M. EST. The previous NR had stated that UNAHCO’s [...]
Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
20/11/2018
reSET ® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment [...]
R1 RCM to Present at the 30th Annual Piper Jaffray Healthcare Conference
20/11/2018
CHICAGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of revenue cycle management and physician advisory services to healthcare providers, today announced its management team will [...]
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
19/11/2018
Phase 1 healthy volunteer study of DNL747 meets all endpoints, including CSF exposure levels, RIPK1 inhibition, and pathway engagement, at doses that were safe and well tolerated Data from the Phase 1 healthy volunteer [...]
Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting
19/11/2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today [...]
XOMA Announces Commencement of Rights Offering
19/11/2018
EMERYVILLE, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of [...]
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
19/11/2018
GAITHERSBURG, Md. and SAINT-HERBLAIN, France, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating [...]
Voyager Therapeutics to Present at the Evercore ISI Healthcare Conference
19/11/2018
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today [...]
Auxly Congratulates Partner ICC International Cannabis Corp on Acquisition of Portuguese Hemp Company
19/11/2018
VANCOUVER, British Columbia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (" Auxly " or the " Company ") is pleased to announce that its strategic international partner, ICC International [...]
Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates
19/11/2018
RUTHERFORD, N.J., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]
EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS
19/11/2018
EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS GAITHERSBURG, Md. and Saint-Herblain, France, November 19, 2018 - Emergent BioSolutions Inc. (NYSE: [...]
Emergent BioSolutions et Valneva annonçent des résultats positifs de Phase 1 pour leur candidat vaccin contre le virus Zika
19/11/2018
Emergent BioSolutions et Valneva annonçent des résultats positifs de Phase 1 pour leur candidat vaccin contre le virus Zika GAITHERSBURG, Md. and Saint-Herblain, France, 19 novembre, 2018 - Emergent BioSolutions Inc. ( [...]
Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors
19/11/2018
Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of life-threatening immune [...]
Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference
19/11/2018
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced today that Pablo J. [...]

Pages